0000000000966143

AUTHOR

Laura Moreno-galarraga

0000-0003-0293-0749

showing 2 related works from this author

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

severe asthmamedicine.medical_specialtyPediatricsImmunology*real lifeOmalizumabhumanized monoclonal antibodiesOmalizumab*adolescentsAntibodies Monoclonal HumanizedAnti-asthmatic Agent03 medical and health sciences0302 clinical medicinechildrenreal lifeInternal medicinemedicine*anti-asthmatic agents*childrenHumansImmunology and AllergyChildren adolescents anti-asthmatic agents humanized monoclonal antibodies observational study omalizumab real-life severe asthmaAnti-Asthmatic Agentsadolescents030212 general & internal medicineChildAdverse effectRetrospective Studiesbusiness.industryasthmatic agents*observational studyanti&#8208Retrospective cohort studyAsthmaDiscontinuation*omalizumabTreatment OutcomePulmonology030228 respiratory system*humanized monoclonal antibodies*severe asthmaSevere persistent allergic asthmaPediatrics Perinatology and Child HealthCohortomalizumabobservational studyObservational studybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct

Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey

2020

CF-COVID19-Spain Registry Group.

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyPneumonia ViralPopulationDiseaseRisk AssessmentCystic fibrosisArticleCystic fibrosisBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinemedicineHumansRegistries030212 general & internal medicineMortalityeducationPandemicsRetrospective Studieseducation.field_of_studyClinical Laboratory Techniquesbusiness.industrySARS-CoV-2IncidenceIncidence (epidemiology)Mortality rateCOVID-19Retrospective cohort studymedicine.diseaseCoronavirus030228 respiratory systemSpainFemaleObservational studyCoronavirus InfectionsRisk assessmentbusiness
researchProduct